Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Dis Colon Rectum. 2019 Nov;62(11):1371–1380. doi: 10.1097/DCR.0000000000001461

Table 2.

Cost-effectiveness of extended venous thromboembolism prophylaxis following surgery for Crohn’s disease versus routine care

Strategy EV cost (US$ 2017) Incremental EV cost (US$ 2017) EV effectiveness (QALYs) Incremental EV effectiveness (QALYs) ICER ($/QALYs) Net Monetary Benefit (US$ 2017) $ per mortality averted
With extended prophylaxis 1,387.95 988.63 22.60873 0.000519 $1,904,328 3,389,921 43,003,456
Routine care 399.832 22.60821 3,390,832

EV, estimated value; QALYs, quality adjusted life years; ICER, incremental cost-effectiveness ratio

Net Monetary Benefit: incremental cost minus willingness-to-pay multiplied by the incremental QALYs